|drug2694||Pulmonary Vascular Permeability Index Wiki||1.00|
|drug1264||Extravascular Lung Water Index Wiki||1.00|
|drug1334||Folic Acid Wiki||1.00|
|D011654||Pulmonary Edema NIH||0.58|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Description: Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or coughMeasure: Lower respiratory tract infection (LRTI) rates Time: 28 days from enrolment
Description: Cumulative incidence of hospitalization or mortalityMeasure: Incidence of hospitalization or mortality Time: Day 28 after enrolment
Description: Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabsMeasure: Change in upper respiratory viral shedding Time: Day 1 through Day 14 after enrolment
Description: COVID-19 symptoms are based on the following criteria: At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing, OR Severe respiratory illness with at least 1 of the following: Clinical or radiological evidence of pneumonia, OR Acute respiratory distress syndrome (ARDS), OR LRTI, defined by resting SpO2<93% sustained for 2 readings 2 hours apart AND presence of subjective dyspnea or cough Death or COVID-19-related hospitalizations will count as a failure to resolve symptoms.Measure: COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only] Time: Day 1 through Day 14 after enrolment
Description: Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuationMeasure: Rate of participant-reported adverse events Time: 28 days from enrolment
Description: Duration of hospitalization among persons who become hospitalized with COVID-19 diseaseMeasure: COVID-19-related hospitalization days Time: 28 days from enrolment
Description: Peak score on WHO Ordinal Scale for Clinical Improvement Peak score on modified inFLUenza patient-reported outcome (Flu-PRO) instrumentMeasure: Rate of disease severity Time: Day 1 through Day 14 after enrolment
Description: Proportion of days with SARS-CoV-2 detected from mid-nasal swabs by PCR Median quantity of SARS-CoV-2 detected from mid-nasal swabs by PCRMeasure: Viral shedding rates Time: Day 1 through Day 14 after enrolment
Description: PK-evaluable participants will have post-hoc individual concentration profiles and exposure estimates determined for exploratory exposure-response analyses against primary and secondary efficacy and safety endpointsMeasure: Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only] Time: 28 days from enrolment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports